Quality of life after curative gastrectomy for gastric cancer in a randomised controlled trial

Chew Wun Wu, Jeng Min Chiou, Feng Shou Ko, Su Shun Lo, Jen Hao Chen, Wing Yiu Lui, J. Whang-Peng

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Quality of life (QOL) was studied in gastric cancer patients treated on a randomised, controlled trial comparing D1 (level 1) with D3 (levels 1, 2 and 3) lymphadenectomy. A total of 221 patients were randomly assigned to D1 (n=110) and D3 (n=111) surgery. Quality-of-life assessments included functional outcomes (a 14-item survey about treatment-specific symptoms) and health perception (Spitzer QOL Index) was performed before and after surgery at disease-free status. Patients suffered from irrelative events such as loss of partners was excluded thereafter. Main analyses were done by intention-to-treat. Thus, 214 D1 (106/110=96.4%) and D3 (108/111=97.3%) R0 patients were assessed. Longitudinal analysis showed that functional outcomes decreased at 6 months after surgery and increased over time thereafter, while health perceptions increased over time in general. On the basis of linear mixed model analyses, patients having total gastrectomy, advanced cancer and hemipancreaticosplenectomy, but not complications had poorer QOL than those without. D1 and D3 patients showed no significant difference in QOL. The results suggest that changes of QOL were largely due to scope of gastric resection, disease status and distal pancreaticosplenectomy, rather than the extent of lymph node dissection. This indicates that nodal dissection can be performed for a potentially curable gastric cancer.

Original languageEnglish
Pages (from-to)54-59
Number of pages6
JournalBritish Journal of Cancer
Volume98
Issue number1
DOIs
Publication statusPublished - Jan 15 2008
Externally publishedYes

Fingerprint

Gastrectomy
Stomach Neoplasms
Randomized Controlled Trials
Quality of Life
Lymph Node Excision
Stomach Diseases
Health
Dissection
Linear Models
Neoplasms

Keywords

  • Gastric cancer
  • Nodal dissection
  • Quality of life
  • Trial

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Quality of life after curative gastrectomy for gastric cancer in a randomised controlled trial. / Wu, Chew Wun; Chiou, Jeng Min; Ko, Feng Shou; Lo, Su Shun; Chen, Jen Hao; Lui, Wing Yiu; Whang-Peng, J.

In: British Journal of Cancer, Vol. 98, No. 1, 15.01.2008, p. 54-59.

Research output: Contribution to journalArticle

Wu, Chew Wun ; Chiou, Jeng Min ; Ko, Feng Shou ; Lo, Su Shun ; Chen, Jen Hao ; Lui, Wing Yiu ; Whang-Peng, J. / Quality of life after curative gastrectomy for gastric cancer in a randomised controlled trial. In: British Journal of Cancer. 2008 ; Vol. 98, No. 1. pp. 54-59.
@article{f585bdc220294d9caf1686948a81da3f,
title = "Quality of life after curative gastrectomy for gastric cancer in a randomised controlled trial",
abstract = "Quality of life (QOL) was studied in gastric cancer patients treated on a randomised, controlled trial comparing D1 (level 1) with D3 (levels 1, 2 and 3) lymphadenectomy. A total of 221 patients were randomly assigned to D1 (n=110) and D3 (n=111) surgery. Quality-of-life assessments included functional outcomes (a 14-item survey about treatment-specific symptoms) and health perception (Spitzer QOL Index) was performed before and after surgery at disease-free status. Patients suffered from irrelative events such as loss of partners was excluded thereafter. Main analyses were done by intention-to-treat. Thus, 214 D1 (106/110=96.4{\%}) and D3 (108/111=97.3{\%}) R0 patients were assessed. Longitudinal analysis showed that functional outcomes decreased at 6 months after surgery and increased over time thereafter, while health perceptions increased over time in general. On the basis of linear mixed model analyses, patients having total gastrectomy, advanced cancer and hemipancreaticosplenectomy, but not complications had poorer QOL than those without. D1 and D3 patients showed no significant difference in QOL. The results suggest that changes of QOL were largely due to scope of gastric resection, disease status and distal pancreaticosplenectomy, rather than the extent of lymph node dissection. This indicates that nodal dissection can be performed for a potentially curable gastric cancer.",
keywords = "Gastric cancer, Nodal dissection, Quality of life, Trial",
author = "Wu, {Chew Wun} and Chiou, {Jeng Min} and Ko, {Feng Shou} and Lo, {Su Shun} and Chen, {Jen Hao} and Lui, {Wing Yiu} and J. Whang-Peng",
year = "2008",
month = "1",
day = "15",
doi = "10.1038/sj.bjc.6604097",
language = "English",
volume = "98",
pages = "54--59",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Quality of life after curative gastrectomy for gastric cancer in a randomised controlled trial

AU - Wu, Chew Wun

AU - Chiou, Jeng Min

AU - Ko, Feng Shou

AU - Lo, Su Shun

AU - Chen, Jen Hao

AU - Lui, Wing Yiu

AU - Whang-Peng, J.

PY - 2008/1/15

Y1 - 2008/1/15

N2 - Quality of life (QOL) was studied in gastric cancer patients treated on a randomised, controlled trial comparing D1 (level 1) with D3 (levels 1, 2 and 3) lymphadenectomy. A total of 221 patients were randomly assigned to D1 (n=110) and D3 (n=111) surgery. Quality-of-life assessments included functional outcomes (a 14-item survey about treatment-specific symptoms) and health perception (Spitzer QOL Index) was performed before and after surgery at disease-free status. Patients suffered from irrelative events such as loss of partners was excluded thereafter. Main analyses were done by intention-to-treat. Thus, 214 D1 (106/110=96.4%) and D3 (108/111=97.3%) R0 patients were assessed. Longitudinal analysis showed that functional outcomes decreased at 6 months after surgery and increased over time thereafter, while health perceptions increased over time in general. On the basis of linear mixed model analyses, patients having total gastrectomy, advanced cancer and hemipancreaticosplenectomy, but not complications had poorer QOL than those without. D1 and D3 patients showed no significant difference in QOL. The results suggest that changes of QOL were largely due to scope of gastric resection, disease status and distal pancreaticosplenectomy, rather than the extent of lymph node dissection. This indicates that nodal dissection can be performed for a potentially curable gastric cancer.

AB - Quality of life (QOL) was studied in gastric cancer patients treated on a randomised, controlled trial comparing D1 (level 1) with D3 (levels 1, 2 and 3) lymphadenectomy. A total of 221 patients were randomly assigned to D1 (n=110) and D3 (n=111) surgery. Quality-of-life assessments included functional outcomes (a 14-item survey about treatment-specific symptoms) and health perception (Spitzer QOL Index) was performed before and after surgery at disease-free status. Patients suffered from irrelative events such as loss of partners was excluded thereafter. Main analyses were done by intention-to-treat. Thus, 214 D1 (106/110=96.4%) and D3 (108/111=97.3%) R0 patients were assessed. Longitudinal analysis showed that functional outcomes decreased at 6 months after surgery and increased over time thereafter, while health perceptions increased over time in general. On the basis of linear mixed model analyses, patients having total gastrectomy, advanced cancer and hemipancreaticosplenectomy, but not complications had poorer QOL than those without. D1 and D3 patients showed no significant difference in QOL. The results suggest that changes of QOL were largely due to scope of gastric resection, disease status and distal pancreaticosplenectomy, rather than the extent of lymph node dissection. This indicates that nodal dissection can be performed for a potentially curable gastric cancer.

KW - Gastric cancer

KW - Nodal dissection

KW - Quality of life

KW - Trial

UR - http://www.scopus.com/inward/record.url?scp=38049052685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049052685&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6604097

DO - 10.1038/sj.bjc.6604097

M3 - Article

C2 - 18182977

AN - SCOPUS:38049052685

VL - 98

SP - 54

EP - 59

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

ER -